S'abonner

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study - 03/12/19

Doi : 10.1016/S1470-2045(19)30663-1 
Sant Chawla, MD a, Jean-Yves Blay, ProfMD b, Piotr Rutkowski, ProfMD c, Axel Le Cesne, MD d, Peter Reichardt, MD e, Hans Gelderblom, ProfMD f, Robert J Grimer, ProfMB BS g, Edwin Choy, MD h, Keith Skubitz, ProfMD i, Leanne Seeger, ProfMD j, Scott M Schuetze, ProfMD k, Robert Henshaw, ProfMD l, Tian Dai, PhD m, Danielle Jandial, MD m, Emanuela Palmerini, MD n,
a Sarcoma Oncology Center, Santa Monica, CA, USA 
b Department of Medicine, Centre Léon Bérard Cancer Center & Université Claude Bernard Lyon, Lyon, France 
c Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland 
d Medical Oncology, Institut Gustave Roussy, Villejuif, France 
e Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany 
f Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands 
g Royal Orthopaedic Hospital, NHS Foundation Trust, Birmingham, UK 
h Division of Hematology & Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 
i Department of Medicine, University of Minnesota, Minneapolis, MN, USA 
j UCLA Health System, Los Angeles, CA, USA 
k Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA 
l Department of Orthopedic Surgery (Orthopedic Oncology), Medstar Georgetown Orthopedic Institute and Washington Cancer Institute, Washington, DC, USA 
m Amgen Inc, Thousand Oaks, CA, USA 
n Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli/Department of Experimental, Diagnostic and Specialty Medicine, Università di Bologna, Bologna, Italy 

* Correspondence to: Dr Emanuela Palmerini, Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli/Department of Experimental, Diagnostic and Specialty Medicine, Università di Bologna, Bologna 40136, Italy Chemotherapy Unit IRCCS Istituto Ortopedico Rizzoli/Department of Experimental Diagnostic and Specialty Medicine Università di Bologna Bologna 40136 Italy

Summary

Background

Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal tumour of the bone. This phase 2 study aimed to assess the safety and activity of denosumab in patients with surgically salvageable or unsalvageable GCTB.

Methods

In this multicentre, open-label, phase 2 study done at 30 sites in 12 countries we enrolled adults and skeletally mature adolescents (aged ≥12 years) weighing at least 45 kg with histologically confirmed and radiographically measurable GCTB, Karnofsky performance status 50% or higher (Eastern Cooperative Oncology Group status 0, 1, or 2), and measurable active disease within 1 year of study enrolment. Patients had surgically unsalvageable GCTB (cohort 1), had surgically salvageable GCTB with planned surgery expected to result in severe morbidity (cohort 2), or were enrolled from a previous study of denosumab for GCTB (cohort 3). Patients received 120 mg subcutaneous denosumab once every 4 weeks during the treatment phase, with loading doses (120 mg subcutaneously) administered on study days 8 and 15 to patients in cohorts 1 and 2 (patients in cohort 3 did not receive loading doses). The primary endpoint was safety in terms of the type, frequency, and severity of adverse events; secondary endpoints included time to disease progression from cohort 1 and the proportion of patients without surgery at month 6 for cohort 2. The safety analysis set included all enrolled patients who received at least one dose of denosumab. This study is registered with ClinicalTrials.gov, number NCT00680992, and has been completed.

Findings

Between Sept 9, 2008, and Feb 25, 2016, 532 patients were enrolled: 267 in cohort 1, 253 in cohort 2, and 12 in cohort 3. At data cutoff on Feb 24, 2017, median follow-up was 58·1 months (IQR 34·0–74·4) in the overall patient population, and 65·8 months (40·9–82·4) in cohort 1, 53·4 months (28·2–64·1) in cohort 2, and 76·4 months (61·2–76·5) in cohort 3. During the treatment phase, the most common grade 3 or worse adverse events were hypophosphataemia (24 [5%] of 526 patients), osteonecrosis of the jaw (17 [3%], pain in extremity (12 [2%]), and anaemia (11 [2%]). Serious adverse events were reported in 138 (26%) of 526 patients; the most common were osteonecrosis of the jaw (17 [3%]), anaemia (6 [1%]), bone giant cell tumour (6 [1%]), and back pain (5 [1%]). 28 (5%) patients had positively adjudicated osteonecrosis of the jaw, four (1%) had atypical femur fracture, and four (1%) had hypercalcaemia occurring 30 days after denosumab discontinuation. There were four cases (1%) of sarcomatous transformation, consistent with historical data. Ten (2%) treatment-emergent deaths occurred (two of which were considered treatment-related; bone sarcoma in cohort 2 and sarcoma in cohort 1). Median time to progression or recurrence for patients in cohort 1 during the first treatment phase was not reached (28 [11%] of 262 patients had progression or recurrence). 227 (92%; 95% CI 87–95) of 248 patients who received at least one dose of denosumab in cohort 2 had no surgery in the first 6 months of the study.

Interpretation

The types and frequencies of adverse events were consistent with the known safety profile of denosumab, which showed long-term disease control for patients with GCTB with unresectable and resectable tumours. Our results suggest that the overall risk to benefit ratio for denosumab treatment in patients with GCTB remains favourable.

Funding

Amgen.

Le texte complet de cet article est disponible en PDF.

Plan


© 2019  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 12

P. 1719-1729 - décembre 2019 Retour au numéro
Article précédent Article précédent
  • Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
  • Theodore W Laetsch, Gary Douglas Myers, André Baruchel, Andrew C Dietz, Michael A Pulsipher, Henrique Bittencourt, Jochen Buechner, Barbara De Moerloose, Kara L Davis, Eneida Nemecek, Timothy Driscoll, Francoise Mechinaud, Nicolas Boissel, Susana Rives, Peter Bader, Christina Peters, Himalee S Sabnis, Stephan A Grupp, Gregory A Yanik, Hidefumi Hiramatsu, Heather E Stefanski, Lawrence Rasouliyan, Lan Yi, Sweta Shah, Jie Zhang, Andrew C Harris
| Article suivant Article suivant
  • Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
  • Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun A Azad, Christian K Kollmannsberger, Bernhard J Eigl, Krista Noonan, Deepa Wadhwa, Andrew Attwell, Bruce Keith, Susan L Ellard, Lyly Le, Martin E Gleave, Alexander W Wyatt, Kim N Chi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.